Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma
| Autor: | Martin Schuler, Dong Wan Kim, Simon J. Harrison, Tae Min Kim, Heike Richly, Alice T. Shaw, A. Yovine, Benjamin Solomon, Anthony Boral |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Pathology Chemotherapy Hematology Anthracycline Ceritinib business.industry Large cell medicine.medical_treatment Immunology Medizin Cell Biology medicine.disease Biochemistry Lymphoma hemic and lymphatic diseases Internal medicine Correspondence medicine Cancer research Anaplastic lymphoma kinase business Anaplastic large-cell lymphoma medicine.drug |
| Zdroj: | Blood. 126:1257-1258 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | To the editor: The anaplastic lymphoma kinase (ALK) gene is expressed in >50% of anaplastic large-cell lymphomas (ALCLs).[1][1] Although most patients with ALK-positive ALCL respond well to anthracycline-based chemotherapy, relapses do occur (5-year failure-free survival 60%) and require salvage |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|